Tierarztl Prax Ausg K Kleintiere Heimtiere 2007; 35(05): 381-387
DOI: 10.1055/s-0038-1622642
Für Studium und Praxis
Schattauer GmbH

Immunvermittelte hämolytische Anämie beim Hund: Therapie und Prognose

A. Balch
1   Las Vegas Veterinary Referral Center, Nevada, USA
,
A. Mackin
2   College of Veterinary Medicine, Mississippi State University, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. Januar 2018 (online)

 

 
  • Literatur

  • 1 Burgess K, Moore A, Rand W. et al Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 2000; 14 (04) 456-462.
  • 2 Scott-Moncrieff JC, Treadwell NG, McCullough SM. et al Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. JAAHA 2001; 37 (03) 220-227.
  • 3 Miller SA, Hohenhaus AE, Hale AS. Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. JAVMA 2004; 224 (02) 232-23.
  • 4 Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: A retrospective study of 72 cases. J Vet Intern Med 2002; 16 (05) 504-509.
  • 5 Stokol T, Blue J, French T. Idiopathic pure red cell aplasia and nonregenerative immune-mediated anemia in dogs: 43 cases (1988–1999). JAVMA 2000; 216 (09) 1429-1436.
  • 6 Weinkle TK, Center SA, Randolph JF. et al Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993–2002). JAVMA 2005; 226 (11) 1869-1880.
  • 7 Klein MK, Dow S, Rosychuk R. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: Ten cases (1982–1987). JAVMA 1989; 195 (02) 246-250.
  • 8 Grundy S, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989–1999). JAVMA 2001; 218 (04) 543-546.
  • 9 Day TK, Macintire DK, Murtaugh RJ. et al Differing opinions on treatment of immune-mediated hemolytic anemia. JAVMA 2001; 218 (09) 1414-1415.
  • 10 Melzer KJ, Wardrop KJ, Hale AS. et al A hemolytic transfusion reaction due to DEA 4 alloantibodies in a dog. J Vet Intern Med 2003; 17 (06) 931-933.
  • 11 Plumb D. Veterinary Drug Handbook. 4th ed. Ames: Iowa State University Press; 2002
  • 12 McCullough S. Immune-mediated hemolytic anemia: Understanding the nemesis. Vet Clin Small Anim 2003; 33: 1295-1315.
  • 13 Reimer ME, Troy GC, Warnick LD. Immunemediated hemolytic anemia: 70 cases (1988–1996). JAAHA 1999; 35 (05) 384-390.
  • 14 Mason N, Duval D, Shofer FS. et al Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune mediated hemolytic anemia in dogs: A randomized controlled clinical trial. J Vet Intern Med 2003; 17 (02) 206-212.
  • 15 Klag A, Giger U, Shofer F. Idiopathic immunemediated hemolytic anemia in dogs: 42 cases (1986–1990). JAVMA 1993; 202 (05) 783-788.
  • 16 Giger U. Regenerative anemias caused by blood loss or hemolysis. In: Textbook of Veterinary Internal Medicine. 6th ed. Ettinger SJ, Feldman EC. eds St Louis: Saunders; 2005: 1886-1907
  • 17 Allenspach K, Rüfenacht S, Sauter S. et al Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. J Vet Intern Med 2006; 20 (02) 239-244.
  • 18 Patricelli AJ, Hardie RJ, McAnulty JE. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. JAVMA 2002; 220 (07) 1009-1016.
  • 19 Adamo FP, O’Brien RT. Use of cyclosporine to treat granulomatous meningoencephalitis in three dogs. JAVMA 2004; 225 (08) 1211-1216.
  • 20 O’Neill T, Edwards GA, Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. J Small Anim Pract 2004; 45 (05) 238-243.
  • 21 Reagan WJ, Scott-Moncrieff C, Christian J. et al Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Am J Vet Res 1998; 59 (12) 1568-1574.
  • 22 Scott-Moncrieff JC, Reagan WJ, Snyder PW. et al Intravenous administration of human im mune globulin in dogs with immune-mediated hemolytic anemia. JAVMA 1997; 210 (11) 1623-1627.
  • 23 Scott-Moncrieff JC, Reagan W. Human intravenous immunoglobulin therapy. Sem Vet Med Surg (Small Anim) 1997; 12 (03) 178-185.
  • 24 Cohn L. Immune mediated blood dyscrasias: Therapeutic options. Proc 22nd Annu Forum Am Coll Vet Intern Med 2004; 326-327.
  • 25 Kellerman DL. Heparin therapy: What we do and don’t know. Proc 16th Annu Forum Am Coll Vet Intern Med 1998; 438-439.
  • 26 Banyard MRC, Hassett RS. The use of mycophenolate mofetil in the treatment of a case of immune-mediated glomerulonephritis in a dog. Aust Vet Pract 2001; 31: 103-106.
  • 27 Charney SC, Bergman PJ, Hohenhaus AE. et al Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990–1996). JAVMA 2003; 222 (10) 1388-1393.
  • 28 Feldman B, Handagama P, Lubberink A. Splenectomy as adjunctive therapy for immune-mediated thrombocytopenia and hemolytic anemia in the dog. JAVMA 1985; 187 (06) 617-619.
  • 29 Toll J, Aronsohn M. Prospective evaluation of medical therapy with or without splenectomy for the treatment of severe immune mediated hemolytic anemia [abstract]. J Vet Intern Med 2003; 17 (03) 383
  • 30 McManus P, Craig L. Correlation between leukocytosis and necropsy findings in dogs with immune mediated hemolytic anemia: 34 cases (1994–1999). JAVMA 2001; 218 (08) 1308-1313.
  • 31 Weiss DJ, Brazzell JL. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006; 20 (03) 682-686.
  • 32 Feldman BF, Madewell BR, O’Neill S. Disseminated intravascular coagulation: Antithrombin, plasminogen and coagulation abnormalities in 41 dogs. JAVMA 1999; 179: 151-154.
  • 33 Thompson MF, Scott-Moncrieff JC, Brooks MB. Effect of a single plasma transfusion on thromboembolism in 13 dogs with primary immune- mediated hemolytic anemia. JAAHA 2004; 40 (06) 446-454.
  • 34 Rozanski E. Management of the hyper-coagulable patient; anticoagulant therapy. Proc Tufts Anim Expo 2002; 221
  • 35 Dunn M, Charland V, Thorneloe C. The use of a low molecular weight heparin in 6 dogs [abstract]. J Vet Intern Med 2004; 18 (03) 389
  • 36 Lunsford K, Mackin A, Langston C. et al Pharmacokinetics of the biological effects of subcutaneous enoxaparin in dogs [abstract]. J Vet Intern Med 2005; 19 (03) 400
  • 37 Duval D, Giger U. Vaccine associated immune mediated hemolytic anemia in the dog. J Vet Intern Med 1996; 10 (05) 290-295.
  • 38 Whelan MF, Rozanski EA, O’Tolle TE. et al Use of the canine hemolytic anemia objective score (CHAOS) to predict survival in dogs with immunemediated hemolytic anemia [abstract]. J Vet Intern Med 2006; 20 (03) 71